GSK’s Dovato Matches Efficacy of Gilead’s Biktarvy with Less Weight Gain in HIV Trial

1. Positive Data from PASO DOBLE Trial: ViiV Healthcare, a unit of GlaxoSmithKline (GSK), announced positive results from the PASO DOBLE trial, demonstrating that Dovato, a 2-drug regimen, is as effective as Gilead's 3-drug regimen Biktarvy for maintenance therapy of HIV-1.
2. Less Weight Gain: The trial showed that Dovato is associated with significantly less weight gain compared to Biktarvy, providing an additional benefit for patients.
3. Head-to-Head Comparison: The PASO DOBLE trial was a head-to-head comparison of Dovato and Biktarvy, with results indicating that Dovato maintained comparable efficacy to Biktarvy.
4. Spanish Trial: The trial was conducted in Spain, providing valuable insights into the performance of Dovato in a real-world setting.
5. ViiV Healthcare's HIV Unit: ViiV Healthcare, GSK's HIV unit, conducted the 48-week trial, which highlighted the potential of Dovato as a competitive treatment option for HIV patients.